Ozempic Displacement Index
GLP-1 drug revenue growing 200%+ YoY. Simultaneously: Pepsi, Mondelez, and Conagra quietly revising guidance.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and the broader class of weight-loss and diabetes drugs — are causing measurable downstream disruption in the packaged food and snack industry. Patients on GLP-1 drugs report significantly reduced appetite, caloric intake, and cravings for ultra-processed foods. The effect is now showing up in the quarterly earnings calls of major snack manufacturers, who are revising volume guidance downward and beginning to reformulate product lines for lower-calorie formats.
Snack and packaged food sector revenue delta modeled from consecutive quarterly earnings guidance revisions at PepsiCo, Mondelez International, and Conagra Brands, cross-referenced with Bloomberg consumer staples sector analysis. GLP-1 drug penetration and revenue data from Novo Nordisk and Eli Lilly company filings and industry analysts.